Compare · ABBV vs SDEV
ABBV vs SDEV
Side-by-side comparison of AbbVie Inc. (ABBV) and Stablecoin Development Corporation (SDEV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and SDEV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $443.36B, about 7641.8x SDEV ($58.0M).
- Over the past year, ABBV is up 27.2% and SDEV is down 61.5% - ABBV leads by 88.8 points.
- ABBV has been more active in the news (7 items in the past 4 weeks vs 6 for SDEV).
- ABBV has more recent analyst coverage (25 ratings vs 0 for SDEV).
- Company
- AbbVie Inc.
- Stablecoin Development Corporation
- Price
- $250.88-2.57%
- $1.15-2.54%
- Market cap
- $443.36B
- $58.0M
- 1M return
- -0.08%
- +11.65%
- 1Y return
- +27.25%
- -61.51%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2012
- News (4w)
- 7
- 6
- Recent ratings
- 25
- 0
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Second-Quarter 2026 Financial Results
- JUVÉDERM® Day Returns to U.S. on August 19
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Latest SDEV
- Stablecoin Development Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results
- SEC Form 10-Q filed by Stablecoin Development Corporation
- Amendment: SEC Form SCHEDULE 13D/A filed by Stablecoin Development Corporation
- SEC Form 3 filed by new insider Blynn Henry
- Stablecoin Development Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Executive Officer Kazley Michael John exercised 11,332,020 in-the-money shares at a strike of $0.00 and sold $26,945 worth of shares (24,720 units at $1.09) (SEC Form 4)
- Large owner Framework Ventures Iv L.P. exercised 11,332,020 in-the-money shares at a strike of $0.00 and sold $26,945 worth of shares (24,720 units at $1.09), increasing direct ownership by 100% to 22,668,516 units (SEC Form 4)
- Large owner R01 Fund Lp exercised 11,332,020 in-the-money shares at a strike of $0.00 and sold $26,945 worth of shares (24,720 units at $1.09), increasing direct ownership by 100% to 22,668,516 units (SEC Form 4)
- Stablecoin Development Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits